Partial
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Some general pharmacology and statin-consistent statements are plausible, but multiple claims are not supported by the provided FDA label excerpts (Sections 1 and 2), and several safety/clinical-effect claims (e.g., cardiovascular event prevention beyond the revascularization/coronary atherosclerosis wording) cannot be verified as on-label from the text provided.
Category Scores
Accurate Statements
Fluvastatin ER is an extended-release formulation of fluvastatin.
Supported by the provided label excerpts referring to 'fluvastatin sodium extended-release tablets' (Sections 1 and 2).
Fluvastatin ER is a statin medication used to lower cholesterol levels.
Supported for LDL-C reduction as an adjunct to diet (Section 1).
Fluvastatin ER works by inhibiting HMG-CoA reductase.
Not verifiable from the provided label excerpts (Sections 1 and 2 only).
Fluvastatin ER reduces cholesterol by blocking the action of HMG-CoA reductase.
Not verifiable from the provided label excerpts (Sections 1 and 2 only).
Inhibition of HMG-CoA reductase leads to decreased production of cholesterol.
Not verifiable from the provided label excerpts (Sections 1 and 2 only).
The extended-release formulation of fluvastatin ER ensures a more consistent level of the drug in the body over time.
Not verifiable from the provided label excerpts (Sections 1 and 2 only).
Fluvastatin ER is designed for extended release.
Supported by labeling term 'extended-release tablets' (Sections 1 and 2).
Fluvastatin ER is used to reduce elevated total cholesterol.
Not directly supported by provided excerpt (Section 1 specifically references LDL-C reduction, not total cholesterol).
Fluvastatin ER is used to reduce LDL ('bad') cholesterol.
Supported: 'reduce LDL-C' as adjunct to diet in adults with primary hyperlipidemia and in adults/pediatric patients with HeFH (Section 1).
Fluvastatin ER is primarily prescribed to treat hyperlipidemia.
Partially supported: Section 1 indicates LDL-C lowering in adults with primary hyperlipidemia; it does not explicitly say 'primarily prescribed' (Section 1).
The dosage of fluvastatin ER prescribed depends on an individual's specific cholesterol-lowering needs and response to treatment.
Not verifiable from provided excerpts; the excerpt provides a fixed 80 mg once daily for the ER tablet (Sections 2 and 2.2/2.3).
Fluvastatin ER belongs to the statin class of drugs.
Not verifiable from provided excerpts (Sections 1 and 2 only).
Fluvastatin ER is usually taken once daily.
Supported: 'Take ... once daily as a single dose' (Section 2).
If a dose of fluvastatin ER is missed, it should be taken as soon as remembered unless it is close to the time for the next scheduled dose.
Not provided in the label excerpts (Sections 1 and 2 only).
If a missed dose of fluvastatin ER is close to the next scheduled dose, the missed dose should be skipped.
Not provided in the label excerpts (Sections 1 and 2 only).
If a missed dose of fluvastatin ER is skipped, the regular dosing schedule should be resumed.
Not provided in the label excerpts (Sections 1 and 2 only).
It is important not to double the dose to make up for a missed dose of fluvastatin ER.
Not provided in the label excerpts (Sections 1 and 2 only).
Unsupported Statements
Fluvastatin ER works by inhibiting HMG-CoA reductase.
Not supported by the provided label excerpts (Sections 1 and 2 only).
HMG-CoA reductase is an enzyme involved in cholesterol production in the liver.
Not supported by the provided label excerpts.
By reducing cholesterol, fluvastatin ER can help prevent cardiovascular events such as heart attacks and strokes.
Section 1 provided specifies reduction of risk of undergoing coronary revascularization procedures and slowing progression of coronary atherosclerosis; it does not mention heart attacks or strokes in the provided excerpt.
Fluvastatin ER reduces cholesterol by blocking the action of HMG-CoA reductase.
Not supported by the provided label excerpts.
Inhibition of HMG-CoA reductase leads to decreased production of cholesterol.
Not supported by the provided label excerpts.
Decreased production of cholesterol causes the liver to take up more LDL cholesterol from the bloodstream.
Not supported by the provided label excerpts.
The primary difference between fluvastatin and fluvastatin ER lies in their formulation and how they release the active ingredient.
Not supported by the provided label excerpts.
Fluvastatin ER gradually releases fluvastatin into the bloodstream over a longer period compared to immediate-release formulations.
Not supported by the provided label excerpts.
Extended release of fluvastatin ER can help maintain more stable cholesterol-lowering effects throughout the day.
Not supported by the provided label excerpts.
Information regarding specific patent expiry dates for fluvastatin ER can be found on specialized patent tracking websites.
Not supported by the provided label excerpts.
Generic versions of fluvastatin ER availability depends on patent expirations and regulatory approvals.
Not supported by the provided label excerpts.
Once patents protecting fluvastatin ER expire, other manufacturers may be able to produce and sell generic fluvastatin ER.
Not supported by the provided label excerpts.
Other manufacturers may be able to produce and sell generic fluvastatin ER typically at a lower cost.
Not supported by the provided label excerpts.
Common side effects associated with fluvastatin ER can include headache, nausea, diarrhea, and muscle aches.
Not supported by the provided label excerpts (no adverse reaction section provided).
More serious side effects associated with fluvastatin ER may involve liver problems.
Not supported by the provided label excerpts (no warnings/adverse reaction section provided).
More serious side effects associated with fluvastatin ER may involve muscle damage (rhabdomyolysis).
Not supported by the provided label excerpts (no warnings/adverse reaction section provided).
Fluvastatin ER is often taken in the evening.
Not supported by the provided label excerpts; the excerpt only states once daily with or without food (Section 2).
Fluvastatin ER is used to reduce triglycerides.
Not supported by the provided label excerpts (Section 1 focuses on LDL-C and coronary indications).
Fluvastatin ER is used to raise HDL ('good') cholesterol.
Not supported by the provided label excerpts.
By reducing cholesterol and raising HDL, fluvastatin ER reduces the risk of atherosclerosis and its complications.
Section 1 provided mentions 'slow the progression of coronary atherosclerosis' and risk reduction for revascularization procedures, but the claim includes raising HDL, which is not in the provided excerpt.
Contradictions
Low
AI Statement
Fluvastatin ER is used to reduce triglycerides.
Label Reference
SECTION 1 provided excerpt
Low
AI Statement
Fluvastatin ER is used to raise HDL ('good') cholesterol.
Label Reference
SECTION 1 provided excerpt
Low
AI Statement
Fluvastatin ER is often taken in the evening.
Label Reference
SECTION 2 provided excerpt
Important Omissions
On-label indication is limited in the provided excerpt to: (1) adults with clinically evident coronary heart disease—reduce risk of undergoing coronary revascularization procedures and slow progression of coronary atherosclerosis; and (2) adjunct to diet for LDL-C reduction in adults with primary hyperlipidemia and adults/pediatric patients ≥10 years with HeFH who require 80 mg daily. The audited response omits these exact labeled coronary-revascularization/atherosclerosis terms and the pediatric HeFH 'require 80 mg' criterion.
Importance:
Moderate
Key administration constraint: the ER tablet is only available as 80 mg and 'cannot be titrated' (and for pediatrics 10+ initiation is not recommended due to available strength). The audited response does not mention the 'cannot be titrated' and 'only available as 80 mg' details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several clinical/safety-adjacent claims (e.g., specific side effects and time-of-day guidance) are not supported by the provided label excerpts; also missing label-specific dosing constraints ('only available as 80 mg', 'cannot be titrated') could affect accurate dosing communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts, including adverse reaction statements and several lipid-parameter indications not reflected in the excerpt (triglycerides, HDL) and the 'evening' dosing habit.
Suggested Improvement
Restrict statements to the provided on-label excerpt: LDL-C reduction as adjunct to diet and the coronary heart disease indication language; for dosing, state ER tablet is only 80 mg, taken once daily with/without food, and cannot be titrated. Remove or qualify unsupported mechanistic, side effect, patent/generic, and dosing-time claims unless supported by additional label sections.